Tag: actions

COMMUNIQUE RELATIF AU DEPOT D’UN PROJET D’OFFRE PUBLIQUE DE RETRAIT SUIVIE D’UN RETRAIT OBLIGATOIRE

COLUMBUS, Ohio, June 05, 2025 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced that as of 5:00 p.m., New York City time, on June 4, 2025 (the “Early Participation Date”), pursuant to and in accordance with its previously announced cash tender offer (the “Tender Offer”), approximately $536,786,000 in aggregate principal amount of the Company’s 9.750% Senior Notes due 2029 (the “Notes”) had been validly tendered and not validly withdrawn on or prior to the Early Participation Date, which, if and when accepted for purchase up to $150,000,000 in aggregate principal amount of Notes (the “Tender Cap”) by the Company pursuant to the terms and conditions of the Tender Offer, would result in Total Consideration (as defined below) (excluding accrued interest payable) of $1,071.25 for each $1,000 principal amount of Notes, which Total Consideration was determined in accordance with the terms of the Tender Offer based on the principal amount of Notes tendered and the Bid Premiums (as defined in the Offer to Purchase (as defined below)) at which such tenders were made.

MISSISSAUGA, Ontario, June 05, 2025 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen“) (TSXV:NXH, OTC:NXHSF), is pleased to announce the results of the annual general of shareholders held on June 4, 2025 (the “Meeting”). All matters presented for approval at the Meeting have been fully authorized and approved. A total of 5,778,769 common shares, representing 25.214% of the common shares issued and outstanding, were represented in person or by proxy at the meeting. A brief description of the matters voted upon and the outcome of the votes is set forth below.

VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- June 5, 2025 – Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics”, “Rubicon” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the closing of its acquisition of an operational, purpose-built 47,500 sq. ft. indoor cultivation facility in Hope, British Columbia. The acquisition is a key milestone in Rubicon’s growth strategy to expand premium and certified organic cannabis production.

Continued GMV growth
Increased Gross margin approximately 210 basis points
Reduced inventory for the eighth consecutive quarter

New leadership focuses on business simplification and brand enablers

COURTOIS S.A.

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie qui développe des anticorps multispécifiques innovants et des conjugués anticorps-médicaments (Biclonics^®, Triclonics^® et ADClonics^®), a annoncé aujourd’hui le lancement d’une offre publique de souscription de ses actions ordinaires (les « Actions de l’offre »). Toutes les actions ordinaires sont proposées par Merus. En outre, Merus prévoit d’accorder aux souscripteurs une option de 30 jours leur permettant d’acheter jusqu’à 15 % supplémentaires des Actions de l’offre (les « Actions optionnelles » et collectivement avec les Actions de l’offre, les « Actions »). L’offre est soumise aux conditions du marché et à d’autres conditions de clôture. Aucune garantie ne saura être donnée quant au fait que l’offre sera réalisée ni le moment auquel cela interviendra ou encore sa taille réelle ou ses modalités.

HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.